Intermune (ITMN) !! Besser als der Markt! Highflyer? - 500 Beiträge pro Seite

[mastermh]

Hallo!

Intermune hat von den heftigen Kursrückschlägen an den Weltmärkten, vor allem Nasdaq, und auch den bei Bios nicht viel mitbekommen! Intermune ist schon im vorletzten BR und im letzten GBI vorgestellt worden! Ich will hier keine neue Aktien entdecken, sondern einfach einen "siedend heißen Wert" (lt. GBR), nicht unbemerkt davon ziehen lassen! Intermune ist Spezialist bei Knochenkrankheiten und steht lt. GBI bei großen Investmenthäusern ganz oben auf der Liste! Die relative Stärke zum Gesamtmarkt ist dennoch beeindruckend! Hier könnte sich wirklich etwas ganz schönes entwickeln, aber wie auch bei anderen Bios: HIGH RISK! But, No Risk, No Fun!! Scherz bei Seite, schaut euch den Wert mal an und schreibt eure Meinung!

ciao mastermh

PS: Gestern noch im PLUS geschlossen

[IWA Japan]

ja so was, aber es gibt auch schon genug Artikel dazu wie diesen etwa Thread: Intermune (ITMN) - wie kommen die auf das Potenzial ?

[mastermh]

@IWA: Ist es schlimm? Habe nur einen Neuen aufgemacht!

Heute ist ITMN etwas in die Knie gegangen, aber bei verhältnismäßig geringen bis sehr geringen Umsätzen! Mal sehen wie der Tag im Ami Land ausklingt! Ich denke, daß die $50 noch erreicht werden und wenn noch ein wenig "Glück" dabei ist werden auch die $52 noch gehalten!


ciao mastermh

[mahatma]

beobachte diese Aktie schon länger , heute habe ich das Gefühl , den Einstieg verpennt zu haben

heute gehts wieder ab !!!! (ca.10 % Plus bis jetzt)

die starke Seite von InterMune http://investor.intermune.com/ireye/ir_site.zhtml?ticker=ITM…


hier der Chart:

gruß maha

[mastermh]

Hallo!

Leider tut sich nicht also viel bei ITMN! Aber, die Umsätze sind doch gestern wieder recht hoch gewesen! In meinen Augen ist es nur noch eine Frage der Zeit, bis dieser Wert ausbricht! Von unten kommen jetzt langsam, aber sich die Durchschnittslinien und dann sollte ITMN mitlaufen und das nicht so schlecht! Wie seht ihr das?

Ciao mastermh

[mastermh]

InterMune to Present at Prudential Vector Healthcare Conference

BURLINGAME, Calif., Nov. 7 /PRNewswire/ -- InterMune (Nasdaq: ITMN) announced that it will present at the Prudential Vector Healthcare Group`s 5th Annual Healthcare Conference at the Hotel Inter-Continental in New York City on Wednesday, November 8, 2000 at 10:45 a.m. (EST). The presentation will be given by W. Scott Harkonen, M.D., President and CEO of InterMune.

Interested parties may access audio of the presentation either live or on a replay basis following the presentation by visiting Prudential Securities` website at www.prudentialsecurities.com and clicking on the "Healthcare Conference Audio" icon.

InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. For more information about InterMune and ACTIMMUNE(R), please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail]. SOURCE InterMune Pharmaceuticals, Inc.

[mastermh]

Connetics Generates $42.2 Million Through the Sale of Intermune Shares

PALO ALTO, Calif., Nov. 16 /PRNewswire/ -- Connetics Corporation (Nasdaq: CNCT) announced today that it has sold 900,000 shares of its holdings in InterMune Pharmaceuticals, Inc. (Nasdaq: ITMN). The sales, which have taken place over the last three weeks, have raised net proceeds for Connetics of approximately $42.2 million. Subsequently, Connetics owns 149,445 shares of InterMune. Connetics` holdings in InterMune are the result of spinning out the company in April 1998. Including cash balances as of September 30, 2000, Connetics has approximately $80 million in cash and cash equivalents.

"We have more than doubled our cash position and are able to invest in the growth of our business without the need for additional financings," said Thomas G. Wiggans, President and Chief Executive Officer. "We are committed to our business strategy focused on revenue growth and late-stage product development. With our financial position and our commercialized products, including the recent launch of OLUX(TM), we believe we have a strong platform to build upon. We look forward to initiating clinical trials with new dermatology products and with relaxin in 2001."

Connetics Corporation, headquartered in Palo Alto, California, is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the dermatology market. In addition, Connetics is developing recombinant human relaxin for multiple therapeutic areas, including cardiovascular disease, peripheral arterial disease and infertility. For more information about Connetics and its products, please visit Connetics` corporate Web site at www.connetics.com, or send e-mail to [e-mail].

This news release contains forward-looking statements about the need to raise additional capital in the future. These statements represent our judgment as of the date of this news release and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. In particular, we face risks and uncertainties that our products may not compete in the markets we describe, or that the size of those markets may vary, which would have a direct impact on our anticipated revenues and need for capital. These and other factors are discussed in more depth in Connetics` Form 10-K for the year ended December 31, 1999, and in the Company`s other filings with the SEC. These documents contain and identify important factors that could cause the actual results to differ materially from those contained in the forward-looking statements. SOURCE Connetics Corporation

[mastermh]

Protein Design Labs and InterMune Announce Antibody Humanization Agreement

FREMONT, Calif. and BURLINGAME, Calif., Nov. 28 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - news) and InterMune Pharmaceuticals, Inc. (Nasdaq: ITMN - news) today announced an agreement under which PDL will humanize an InterMune monoclonal antibody targeted to the bacteria Pseudomonas aeruginosa.
Pseudomonas aeruginosa is a bacterium that often affects patients using respirators and catheters as well as patients with a number of conditions, including ventilator-associated pneumonia, burns, low white blood cell counts and cystic fibrosis. The target of the monoclonal antibody, PcrV, is a membrane protein on Pseudomonas aeruginosa that facilitates the virulence, or disease-causing ability of these bacteria. The antibody has been shown to be effective in preclinical animal models of infection.

PDL will receive an upfront fee and will be entitled to milestone payments upon the achievement of specified objectives, annual maintenance payments and royalties on any product sales. Detailed financial terms were not disclosed. PDL recognizes upfront fees from humanization contracts over the period in which the work is conducted, typically several months.

``This is an exciting new program for InterMune, one that addresses sizeable new markets that compliment our ongoing programs with ACTIMMUNE®,`` said John J. Wulf, Senior Vice President of Corporate Development at InterMune. ``We are pleased to be working with PDL for humanization of our monoclonal antibody against PcrV for potential treatment and prevention of infection by Pseudomonas aeruginosa in high-risk patients. PDL is an established leader in humanization technology and has a proven track record in the successful humanization of antibodies for therapeutic use.``

``We are pleased that InterMune has chosen to work with PDL to humanize this antibody,`` said Robert L. Kirkman, M.D., PDL`s Vice President, Business Development and Corporate Communications. ``This year, PDL has signed agreements to humanize six antibodies for pharmaceutical and biotechnology companies, the most in PDL`s history. In addition, we have signed patent license or patent rights agreements covering nine antibodies. We believe these agreements are a continuing recognition of the fundamental value of the humanization technology and the success which humanized antibodies are having in the clinic and on the market.`` PDL receives royalties on sales of all four of the currently marketed humanized antibodies. PDL is aware of over 40 additional humanized antibodies in clinical trials.

Protein Design Labs, Inc. is a leader in the development of humanized antibodies to prevent or treat various disease conditions. PDL currently has antibodies under development for autoimmune and inflammatory conditions, asthma and cancer. PDL holds fundamental patents in the U.S., Europe and Japan for its antibody humanization technology. For further information, visit www.pdl.com.

InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE® (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. For more information about InterMune and ACTIMMUNE®, please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks of Protein Design Labs, Inc. ACTIMMUNE is a registered trademark of InterMune Pharmaceuticals, Inc.

SOURCE: Protein Design Labs, Inc.

[mastermh]

Etwas verspätet, aber dennoch:

InterMune Files New Drug Submission for Actimmune(R) in Canada

BURLINGAME, Calif., Jan. 3 /PRNewswire/ -- InterMune (Nasdaq: ITMN) announced today that it has filed a New Drug Submission (NDS) with the Therapeutic Products Programme of Health Canada (TPP) to market ACTIMMUNE(R) (Interferon gamma-1b) in Canada for chronic granulomatous disease (CGD) and severe, malignant osteopetrosis, both life-threatening childhood diseases. The TPP has granted Priority Review status to the NDS, and the Company expects approval within six months, as there are no other effective treatments available for these diseases. ACTIMMUNE(R) is currently marketed in the United States for CGD and severe, malignant osteopetrosis.

"In the United States, physicians have more than ten years of experience using ACTIMMUNE(R) in children," said W. Scott Harkonen, M.D., CEO and President of InterMune. "In Canada there is currently no effective treatment approved for CGD or osteopetrosis, and with ACTIMMUNE`s strong safety record, we look forward to ACTIMMUNE(R) being available to Canadian physicians and patients."

In 1990, the U.S. Food and Drug Administration (FDA) approved ACTIMMUNE(R) for reducing the frequency and severity of serious infections associated with CGD, a rare, inherited deficiency of the immune system that leaves patients vulnerable to frequent and severe bacterial and fungal infections. These infections often require hospitalization and can be fatal.

In February 2000, the FDA approved ACTIMMUNE(R) for delaying the time to disease progression in patients with severe, malignant osteopetrosis. Severe, malignant osteopetrosis is a life-threatening congenital disorder in which an overgrowth of bony structures leads to blindness, deafness and increased susceptibility to infection. ACTIMMUNE(R) is the only FDA-approved treatment for severe, malignant osteopetrosis or CGD.

InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. For more information about InterMune and ACTIMMUNE,(R) please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

Except for the historical information contained herein, this press release contains certain forward-looking statements, concerning the possible benefits of interferon gamma for treating CGD and severe, malignant osteopetrosis, that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune`s actual results could differ materially from those described in InterMune`s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: even if InterMune`s potential CGD and severe, malignant osteopetrosis products appear promising at an early stage of development, they may not reach the market for a number of reasons. Such reasons include, but are not limited to, the possibilities that the potential products will fail to receive the necessary regulatory approvals, be uneconomical to market, be precluded from commercialization by the proprietary rights of third parties; or fail to be as safe or effective and/or cost more than competitors` products that may be approved by the TPP. Other factors that could cause or contribute to such differences include, but are not limited to those discussed under the heading "Risk Factors" and the risks and factors discussed in InterMune`s Registration Statement on Form S-1, declared effective on October 30, 2000 by the Securities and Exchange Commission (File No. 333-45460), and InterMune`s most recent 10-Q filed with the U.S. SEC.
SOURCE InterMune

ciao mastermh

[mastermh]

Und noch etwas:

InterMune Initiates Phase II Trial of Actimmune(R) in the Treatment of Atypical Mycobacterial Infections

BURLINGAME, Calif. – January 3, 2001 -- InterMune (Nasdaq: ITMN) announced today that it has commenced enrollment in its Phase II clinical trial evaluating the safety and efficacy of inhaled ACTIMMUNE® (Interferon gamma-1b) for the treatment of pulmonary atypical mycobacterial infections. Atypical mycobacteria cause a wide spectrum of diseases in humans and are difficult to treat with current therapy.

“The start of this trial is a significant step in our continuing efforts to establish ACTIMMUNE® as a therapy for serious infectious diseases,” said W. Scott Harkonen, M.D., CEO and President of InterMune. “InterMune now has three late-stage clinical trials ongoing with ACTIMMUNE® for the treatment of serious infections, in addition to our ongoing Phase III trial in idiopathic pulmonary fibrosis (IPF).”

Atypical mycobacterial infections frequently occur in immunocompromised patients, such as HIV and cancer patients, as well as in elderly individuals. The current treatment for atypical mycobacterial infections consists of prolonged administration of antibiotics, often for two years or more. InterMune initiated the Phase II trial for atypical mycobacterial infections based upon positive clinical results published in The New England Journal of Medicine in May 1994. The results showed that ACTIMMUNE®, in combination with conventional therapy, was successful in reducing fever and other signs of infection in patients with atypical mycobacterial infections.

InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE® (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. For more information about InterMune and ACTIMMUNE®, please visit InterMune’s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

Except for the historical information contained herein, this press release contains certain forward-looking statements, concerning the possible benefits of interferon gamma for treating atypical mycobacterial infections, that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune’s actual results could differ materially from those described in InterMune’s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: even if InterMune’s potential atypical mycobacterial infections products appear promising at an early stage of development, they may not reach the market for a number of reasons. Such reasons include, but are not limited to, the possibilities that the potential products will be found ineffective during clinical trials, fail to receive the necessary regulatory approvals, be difficult to manufacture on a large scale, be uneconomical to market, be precluded from commercialization by the proprietary rights of third parties; or fail to be as safe or effective and/or cost more than competitors’ atypical mycobacterial infections products that may be approved by the U.S. FDA. Other factors that could cause or contribute to such differences include, but are not limited to those discussed under the heading “Risk Factors” and the risks and factors discussed in InterMune’s Registration Statement on Form S-1, declared effective on October 30, 2000 by the Securities and Exchange Commission (File No. 333-45460), and InterMune’s most recent 10-Q filed with the SEC. In sum, these significant risks include, but are not limited to: the uncertainty of success of InterMune’s efforts in research, development, commercialization, product acceptance, third-party manufacturing and capital raising; product liability lawsuits; uncertainties associated with: obtaining and enforcing patents important to its business, being an early-stage company and relying on third-party payors’ reimbursement policies; the uncertain, lengthy and expensive regulatory process; and competition from other products.

ciao mastermh

Ich verzichte auf Interpretationen, da in diesem Umfeld(Markt) alles als Negativ aufgefasst wird!

[mastermh]

InterMune to Present at J.P. Morgan H&Q Healthcare Conference

BURLINGAME, Calif., Jan. 9 /PRNewswire/ -- InterMune (Nasdaq: ITMN) announced that it will present at the J.P. Morgan H&Q 19th Annual Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 10, 2001 at 9:30 a.m. PST. The presentation will be given by W. Scott Harkonen, M.D., President and CEO of InterMune. Dr. Harkonen will discuss the status and prospects for the Company.

Interested parties may access audio of the presentation either live or on a replay basis following the presentation by visiting the J.P. Morgan H&Q website at www.jpmhq.com.

InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. For more information about InterMune and ACTIMMUNE(R), please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].
SOURCE InterMune Pharmaceuticals, Inc

[Piddy]

@master
du auch in ITMN?
dachte ich wär der einzige in germany.
sind ja in den letzten tagen ziemlich runter gekommen.
gestern haben sie sich von ihrem tagestief aber noch gut
erholt.hoffen wir mal das es das jetzt war.
habe aber eh nicht verkauft,weil ich davon ausgehe das
von ITMN noch vieles positives zu rauskommen wird.
auf hin und her hab ich eh keine lust.warum sollte ich
auch gutes verkaufen....
gruss,piddy

[mastermh]

Hallo piddy!
Nach den Umsätzen (fast nur Tax) in D schätze ich auch dass nur sehr wenige ITMN kennen!
Ich versuche die News hier zu posten und dann soll jeder entscheiden ob er investieren will! Für mich ist der Kursverfall nicht so recht zu erklären, aber die News häufen sich stark in letzter Zeit! Roberts & Stephenson haben ITMN neulich wieder zum Kauf empfohlen!


InterMune Acquires Amphotec(R) From ALZA

BURLINGAME, Calif. and MOUNTAIN VIEW, Calif., Jan. 10 /PRNewswire/ -- InterMune (Nasdaq: ITMN) and ALZA Corporation (NYSE: AZA) announced today that InterMune has acquired worldwide rights to Amphotec(R) from ALZA. The transaction terms include an upfront license fee of $9.0 million, milestone payments based upon sales levels and the development of Amphotec(R) in combination with ACTIMMUNE(R), and royalties payable upon net sales levels. Amphotec(R) is an FDA-approved lipid-complexed form of amphotericin B indicated for the treatment of invasive aspergillosis, a life-threatening fungal infection.

Data published in the September 2000 issue of the Journal of Antimicrobial Chemotherapy showed that in mouse models of cryptococcal fungal infection, ACTIMMUNE(R) was synergistic with amphotericin B in significantly reducing the levels of infection. In one experiment, 78 percent of mice were completely cured when ACTIMMUNE(R) was added to conventional therapy with amphotericin B, compared to 10 percent with amphotericin B alone. Several other published studies have shown similar results in systemic fungal infections.

"Amphotec(R) is a solid fit for InterMune as it provides synergy on two levels with our existing Actimmune(R) programs," said W. Scott Harkonen, M.D., CEO and President of InterMune. "First, it will provide us with the opportunity to develop ACTIMMUNE(R) in combination with Amphotec(R) for systemic fungal diseases. Towards the end of this year we are expecting the results of our ongoing Phase II trial for ACTIMMUNE(R) in combination with standard amphotericin B for cryptococcal meningitis, a life-threatening systemic fungal infection. Second, it will leverage our team of 60 field specialists, all of whom will be trained and in place by July of this year. This gives them a second product to speak about with physicians along with ACTIMMUNE(R)."

"We believe that Amphotec(R) has significant potential given proper support in its target market. With InterMune`s strength in marketing ACTIMMUNE(R), they are ideally positioned to maximize the potential of Amphotec(R) in the infectious disease market," said Sam Saks, M.D., Group Vice President of ALZA Pharmaceuticals. "This agreement is consistent with ALZA`s overall growth strategy as we continue to strengthen our effective sales and marketing presence in the oncology, central nervous system, primary care and urology markets."

Amphotec(R) is sold outside of the United States as Amphocil(R) in more than 20 countries. The product was originally developed by SEQUUS Pharmaceuticals, Inc., which was acquired by ALZA in 1999. Worldwide gross revenues for Amphotec(R) were approximately $4 million in 2000. Amphotec(R) has not been aggressively marketed to physicians for the past two years.

InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. For more information about InterMune and ACTIMMUNE(R), please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

ALZA Corporation, headquartered in Mountain View, California, is a research-based pharmaceutical company with leading drug delivery technologies. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world`s leading pharmaceutical companies. ALZA`s sales and marketing efforts are currently focused in urology, oncology and central nervous system products. ALZA news releases can also be found on the World Wide Web at www.alza.com.

Except for the historical information contained herein, this press release contains certain forward-looking statements, concerning the possible clinical and financial benefits to InterMune in connection with its acquisition of Amphotec(R)/Amphocil(R), that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available as of the date hereof, and InterMune and ALZA assume no obligation to update any such forward-looking statements or information. InterMune`s and ALZA`s actual results could differ materially from those described in any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: the possibilities that the product will be uneconomical to market, be precluded from commercialization by the proprietary rights of third parties or fail to be as commercially acceptable as and/or cost more than competitors` products. Other factors that could cause or contribute to such differences include, but are not limited to those discussed under the heading "Risk Factors" and the risks and factors discussed in ALZA`s most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission; and InterMune`s Registration Statement on Form S-1, declared effective on November 8, 2000 by the Securities and Exchange Commission (File No. 333-45460), and InterMune`s most recent 10-Q filed with the SEC. In sum, these significant risks include, but are not limited to: the uncertainty of success of InterMune`s efforts in product acceptance, third-party manufacturing and capital raising; product liability lawsuits; uncertainties associated with: obtaining and enforcing patents important to its business, being an early-stage company and relying on third-party payors` reimbursement policies; the uncertain, lengthy and expensive regulatory process; and competition from other products.
SOURCE InterMune Pharmaceuticals, Inc.

ciao mastermh

[mastermh]

InterMune Announces Hiring of James Pennington, M.D. as Executive Vice President of Medical and Scientific Affairs

BURLINGAME, Calif., Jan. 23 /PRNewswire/ -- InterMune (Nasdaq: ITMN) announced today the appointment of James E. Pennington, M.D. to the position of Executive Vice President of Medical and Scientific Affairs.

Dr. Pennington has over 14 years of experience in the pharmaceutical industry. Most recently, he was Senior Vice President of Research, Development and Clinical Affairs at Alpha Therapeutic Corporation in Los Angeles. Prior to joining Alpha, Dr. Pennington spent 11 years with Bayer Corporation`s Pharmaceutical Division where he served as Vice President of Biological Clinical Research. Before entering the pharmaceutical industry, Dr. Pennington spent 12 years as a member of the Harvard Medical School faculty. He is board certified in internal medicine, has a subspecialty in infectious diseases and holds an M.D. from the University of Oregon School of Medicine.

"Jim has significant experience in the pharmaceutical industry and a strong academic background in medicine. His special expertise in the areas of pulmonary and infectious diseases fits squarely within InterMune`s ongoing development programs for ACTIMMUNE(R) and Amphotec(R)," said W. Scott Harkonen, M.D., CEO and President of InterMune. "Jim is a strong and experienced manager who will join InterMune at a time when we are expanding our clinical trial programs and strengthening our pipeline."

In 2001 InterMune will have three Phase III trials underway. The company has begun Phase III trials for ACTIMMUNE(R) for the treatment of idiopathic pulmonary fibrosis (IPF) and multidrug-resistant tuberculosis (MDR TB). A Phase III trial for ACTIMMUNE(R) for the treatment of ovarian cancer will begin in the second half of this year. The company will also have active Phase II trials for ACTIMMUNE(R) for the treatment of pulmonary atypical mycobacterial infections, systemic fungal infections and cystic fibrosis in 2001.

InterMune recently announced its acquisition of worldwide rights to Amphotec(R) from ALZA Corporation. Amphotec(R) is an FDA-approved lipid-complexed form of amphotericin B marketed for the treatment of invasive aspergillosis, a life-threatening fungal infection. The company will aggressively market Amphotec(R) by leveraging a team of 60 field specialists, all of whom will be trained and in place by July of this year. Amphotec(R) will be marketed to physicians together with the company`s lead product, ACTIMMUNE(R) (Interferon gamma-1b), which is marketed for chronic granulomatous disease (CGD) and severe, malignant osteopetrosis.

InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. For more information about InterMune and ACTIMMUNE(R), please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

Except for the historical information contained herein, this press release contains certain forward-looking statements, concerning InterMune`s clinical development and marketing goals for the year 2001, that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune`s actual results could differ materially from those described in InterMune`s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed under the heading "Risk Factors" and the risks and factors discussed in InterMune`s Registration Statement on Form S-1, declared effective on November 8, 2000 by the Securities and Exchange Commission (File No. 333-45460), and InterMune`s most recent 10-Q filed with the SEC. In sum, these significant risks include, but are not limited to: the uncertainty of success of InterMune`s efforts in research, development, commercialization, product acceptance, third-party manufacturing and capital raising; product liability lawsuits; uncertainties associated with: obtaining and enforcing patents important to its business, being an early-stage company and relying on third-party payors` reimbursement policies; the uncertain, lengthy and expensive regulatory process; and competition from other products.

SOURCE InterMune Pharmaceuticals, Inc.

ciao mastermh

PS: klingt doch recht nett! :-) Die wird laufen und wie!!

[mastermh]

InterMune Expands U.S. Marketing and Sales Efforts

BURLINGAME, Calif., Jan. 30 /PRNewswire/ -- InterMune (Nasdaq: ITMN) announced today the expansion of its U.S. marketing and sales efforts. The company recently completed the recruitment and training of 24 immunology specialists who are now in the field supporting physicians regarding the safe and appropriate use of ACTIMMUNE(R) (Interferon gamma-1b). This brings the number of InterMune field specialists to 36. InterMune plans to hire and train another 24 immunology specialists by July of this year, bringing the total field force to 60.

Along with the expansion of the field force, InterMune recently hired David Happel as Senior Director of InterMune`s Pulmonary Business Unit, reporting to David Cory, Vice President of Sales and Marketing. In addition to his focus in pulmonology, Mr. Happel will be heading up InterMune`s 60-person field force. Mr. Happel brings 15 years of sales and medical marketing experience to InterMune and most recently was Director, Cardiovascular Global Strategy and Medical Marketing at Warner Lambert, Parke-Davis where he managed several compounds in development and post launch, including Accupril(R).

"David has significant experience in the pharmaceutical industry with a strong sales and marketing background. As we expand our group of field specialists and bring on new products, such as Amphotec(R), David will be key to achieving InterMune`s aggressive sales goals," said W. Scott Harkonen, M.D., CEO and President of InterMune. "2001 is looking to be an exciting year for InterMune as we roll out our expanded commercial effort."

InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis and is in Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and multidrug-resistant tuberculosis (MDR TB). The company also markets Amphotec(R), an FDA-approved lipid-complexed form of amphotericin B marketed for the treatment of invasive aspergillosis, a life-threatening fungal infection. For more information about InterMune and ACTIMMUNE(R), please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

Except for the historical information contained herein, this press release contains certain forward-looking statements, concerning InterMune`s personnel hiring and marketing goals for the year 2001, that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune`s actual results could differ materially from those described in InterMune`s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed under the heading "Risk Factors" and the risks and factors discussed in InterMune`s Registration Statement on Form S-1, declared effective on November 8, 2000 by the Securities and Exchange Commission (File No. 333-45460), and InterMune`s most recent 10-Q filed with the SEC. In sum, these significant risks include, but are not limited to: the uncertainty of success of InterMune`s efforts in research, development, commercialization, product acceptance, third-party manufacturing and capital raising; product liability lawsuits; uncertainties associated with: obtaining and enforcing patents important to its business, being an early-stage company and relying on third-party payors` reimbursement policies; the uncertain, lengthy and expensive regulatory process; and competition from other products. SOURCE InterMune Pharmaceuticals, Inc.

wieder mal was nettes zu lesen!

ciao mastermh

PS: Wer ist denn in ITMN? In D wird ja nur getaxt! :-)

[mastermh]

InterMune Announces Fourth Quarter 2000 Financial Results and Conference Call

BURLINGAME, Calif., Feb. 15 /PRNewswire/ -- InterMune (Nasdaq: ITMN) today announced financial results for the fourth quarter ended December 31, 2000. InterMune reported a net loss of $6.3 million, or $0.27 per share on a pro forma basis, compared to a net loss of $2.1 million, or $0.23 per share on a pro forma basis for the same period in 1999. For the year ended December 31, 2000, InterMune reported a net loss of $52.0 million, or $2.61 per share on a pro forma basis, compared to a net loss of $6.3 million, or $0.82 per share on a pro forma basis for the same period in 1999.

In connection with InterMune`s initial public offering, the fiscal year 2000 financial results include a deemed dividend of $27.8 million upon the issuance of Series B redeemable convertible preferred stock in the first quarter of 2000. Excluding the effect of this expense item, the pro forma net loss per share for the year ended December 31, 2000 would have been $1.22 per share. Pro forma net loss per share amounts assume conversion of preferred stock to common stock at the time of the preferred stock`s original issue. Pro forma net loss per share for fiscal year 1999 also reflects the common and preferred stock issued on April 27, 1999 in connection with the reorganization as though they had been outstanding for the entire year.

Sales of ACTIMMUNE(R) for the fourth quarter were $4.2 million compared to $1.6 million in the fourth quarter of 1999, an increase of 161%. Sales of ACTIMMUNE(R) for the year ended December 31, 2000 were $13.0 million compared to $5.4 million for the same period in 1999, an increase of 142%. On June 28, 2000, the Company announced that it had bought all the rights to ACTIMMUNE(R) revenues from Connetics Corporation (Nasdaq: CNCT) that it did not already own and would book all ACTIMMUNE(R) revenues and related expenses in the United States beginning in the second quarter of 2000.

"We are very pleased with the continued growth in sales of ACTIMMUNE(R) for the quarter, especially since this growth occurred in parallel with the enrollment of our Phase III trial for ACTIMMUNE(R) in idiopathic pulmonary fibrosis (IPF)," said W. Scott Harkonen, M.D., President and CEO of InterMune. "We are also excited to have hired and placed 26 immunology specialists into the field in January. As we add additional immunology specialists in June, for a total of 60 field specialists, and complete enrollment of our Phase III trial for IPF in mid-2001, we expect to see strong continued growth for ACTIMMUNE(R). We exceeded our 2000 revenue goal by over $1 million and we reiterate our 2001 revenue goal for ACTIMMUNE(R) of $24 million, or 100% growth over our 2000 revenue goal of $12 million. In addition, we will have three ongoing Phase III trials and multiple Phase II trials for ACTIMMUNE(R) this year, which will produce a steady stream of clinical results over the next 12 to 36 months," stated Dr. Harkonen.

Amortization expense of $1.8 million was incurred for the year ended December 31, 2000, relating to product revenue rights for ACTIMMUNE(R) acquired from Connetics Corporation. Research and development expenses were $18.1 million for the year ended December 31, 2000, compared to $2.9 million in the same period in 1999. The increase was due primarily to increased costs for clinical trial expenses for ACTIMMUNE(R) in new disease indications and expenses associated with manufacturing transfer costs for ACTIMMUNE(R) at an additional facility. Selling, general and administrative expenses were $12.1 million and $2.4 million for the year ended December 31, 2000, and 1999, respectively. This increase is attributable primarily to increased staffing and related expenses necessary to support the expansion of the Company`s operations. At December 31, 2000, the Company`s cash, cash equivalents and short-term investments totaled $194.5 million.

Highlights from the Fourth Quarter of 2000

Initiated enrollment in Phase III clinical trial evaluating the safety and efficacy of ACTIMMUNE(R) for the treatment of IPF.

Commenced arrangement with Protein Design Labs, Inc. (Nasdaq: PDLI) to humanize an InterMune monoclonal antibody targeted to the bacteria Pseudomonas aeruginosa.

Filed a New Drug Submission (NDS) with the Therapeutic Products Programme of Health Canada to market ACTIMMUNE(R) in Canada for chronic granulomatous disease (CGD) and severe, malignant osteopetrosis.

Initiated enrollment in Phase II clinical trial evaluating the safety and efficacy of inhaled ACTIMMUNE(R) for the treatment of pulmonary atypical mycobacterial infections.

Completed acquisition of Amphotec(R), an FDA-approved lipid-complexed form of amphotericin B, from ALZA Corporation (NYSE: AZA). (Jan. 2001)

Appointed James E. Pennington, M.D. to the position of Executive Vice President of Medical and Scientific Affairs. (Jan. 2001)

Trained and placed into the field 26 immunology specialists to support physicians regarding the safe and appropriate use of ACTIMMUNE(R) and Amphotec(R). (Jan. 2001)

InterMune`s 2001 Financial Outlook

Net revenue goal for ACTIMMUNE(R) of $24 million in 2001. Quarterly goals for ACTIMMUNE(R) of $4.6 million in the first quarter, $5.2 million in the second quarter, $6.4 million in the third quarter, and $7.8 million in the fourth quarter of 2001.

In addition to its quarterly revenue goals, the Company also plans to complete enrollment in its 260-patient trial in IPF by mid-2001.

Net revenue for Amphotec(R) is expected to be approximately $2-4 million in 2001. The Company plans to re-launch Amphotec(R) in the second quarter and is exploring the potential for additional studies, including studies in combination with ACTIMMUNE(R).

Research and development expenses are expected to be approximately $32 million in 2001. The figure reflects the expansion of InterMune`s development programs for ACTIMMUNE(R), such as programs for ovarian cancer and cystic fibrosis, and the advancement of our monoclonal antibody program targeting Pseudomonas aeruginosa.

Selling, general and administrative expenses are expected to be approximately $24 million in 2001. The figure reflects the acceleration of the Company`s sales and marketing plans and the lease of a 55,000 square foot headquarters and pre-clinical development facility.

Net loss for 2001 is expected to be approximately $36 million.

The Company will hold a conference call with research analysts at 11:00 a.m. Eastern Time on Friday, February 16, 2001. Interested investors and others may listen to the call either live or on a replay basis through our internet webcast, which may be accessed by visiting our website at http://www.intermune.com and clicking on the "Investor Relations" icon.

InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis and is in Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis and multidrug-resistant tuberculosis (MDR TB). The Company also markets Amphotec(R), an FDA-approved lipid-complexed form of amphotericin B, for the treatment of invasive aspergillosis, a life-threatening fungal infection. For more information about InterMune and ACTIMMUNE(R), please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

Except for the historical information contained herein, this press release contains certain forward-looking statements concerning InterMune`s clinical, personnel hiring, marketing, sales and financial goals for the year 2001 that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune`s actual results could differ materially from those described in InterMune`s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed under the heading "Risk Factors" and the risks and factors discussed in InterMune`s Registration Statement on Form S-1, declared effective on November 8, 2000 by the Securities and Exchange Commission (File No. 333-45460), and InterMune`s most recent 10-Q filed with the SEC. In sum, these significant risks include, but are not limited to: the uncertainty of success of InterMune`s efforts in research, development, commercialization, product acceptance, third-party manufacturing and capital raising: the uncertain, lengthy and expensive regulatory process; uncertainties associated with: obtaining and enforcing patents important to its business, being an early-stage company and relying on third-party payors` reimbursement policies; competition from other products; and product liability lawsuits.

InterMune Pharmaceuticals, Inc.

CONDENSED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share amounts)


Three Months Ended Year Ended
December 31, December 31,
2000 1999 2000 1999

Product sales, net $4,237 $556 (a) $11,201 (a) $556 (a)

Costs and expenses:
Cost of goods sold 1,593 240 4,990 240
Amortization of
product revenue rights -- -- 1,777 --
Research and
development 6,156 1,129 18,149 2,883
Selling, general and
administrative 4,456 898 12,145 2,397
Deferred compensation 1,552 345 6,679 345
Acquired pre-FDA
approval rights -- -- -- 1,094
Total costs and
expenses 13,757 2,612 43,740 6,959

Loss from operations (9,520) (2,056) (32,539) (6,403)

Interest income, net 3,222 (16) 8,293 54

Net loss (6,298) (2,072) (24,246) (6,349)
Preferred stock
accretion -- (246) (269) (657)
Redeemable preferred
stock dividend -- -- (27,762) --

Net loss attributable
to common stockholders $(6,298) $(2,318) $(52,277) $(7,006)

Historical basic and
diluted net loss
per share $(0.27) $(1.93) $(3.05) $(9.12)
Shares used in
calculating historical
basic and diluted net
loss per common share 22,945 1,204 17,114 768

Pro forma basic and
diluted net loss
per share $(0.27) $(0.23) $(2.61) $(0.82)
Shares used in
calculating pro forma
basic and diluted net
loss per common share 22,945 9,039 19,945 7,770


(a) Sales of ACTIMMUNE(R) up to a contractual threshold of (in thousands) $1,070, $1,827 and $4,833 were reported by Connetics Corporation for the respective periods.

InterMune Pharmaceuticals, Inc.

CONDENSED BALANCE SHEETS
(unaudited, in thousands)


December 31, December 31,
2000 1999
Cash, cash equivalents and short-term
investments $194,520 $4,214
Other assets 7,129 1,641
Total assets $201,649 $5,855

Current liabilities $5,848 $4,355
Long-term obligations -- 1,624
Redeemable convertible preferred stock -- 7,416
Stockholders` equity (deficit) 195,801 (7,540)
Total liabilities and stockholders`
equity $201,649 $5,855


SOURCE InterMune Pharmaceuticals, Inc.

[mastermh]

Eigentlich zu unrecht unter die Räder gekommen, aber doch schon sehr gut erholt! Aus Zeitgründen konnte ich diesen Beitrag nicht fortsetzen, aber jetzt versuche ich es wieder!

InterMune Pharmaceuticals, Inc. (ITMN) Completes Enrollment In Phase II Trial For Fungal Infections And Initiates Clinical Programs In Japan



BURLINGAME, Calif., April 5 /PRNewswire/ -- InterMune (Nasdaq: ITMN) announced today that it has completed enrollment in its first human trial with ACTIMMUNE(R) for the treatment of systemic fungal disease. The Phase II trial has enrolled 79 patients with cryptococcal meningitis, a life-threatening fungal infection, to evaluate the safety and efficacy of ACTIMMUNE(R) in combination with amphotericin B. Results are expected in the fourth quarter of 2001.

Cryptococcal meningitis is a difficult-to-treat, life-threatening infection. Only 60% of patients respond to standard treatment, which is usually amphotericin B. A study published in the Journal of Antimicrobial Chemotherapy in September 2000 showed that in mouse models of cryptococcal fungal infection, combination therapy using ACTIMMUNE(R) and amphotericin B cured 78% of the infected mice, while amphotericin B alone cured only 10%.

"We are very excited to complete enrollment in this trial, and look forward to the results of this first study utilizing this promising new combination," said W. Scott Harkonen, M.D., President and CEO of InterMune. "This therapy looks particularly exciting on the heels of our acquisition of Amphotec(R) and our recent international strategic partnership with Boehringher Ingelheim, which includes the global development of ACTIMMUNE(R) for life-threatening fungal diseases."

InterMune also announced the initiation of a clinical program for ACTIMMUNE(R) in Japan, where it maintains infectious disease rights. ACTIMMUNE(R) is not yet approved in Japan, and the Company recently initiated a Phase I clinical trial there evaluating the safety of inhaled ACTIMMUNE(R) in healthy volunteers. InterMune plans to develop the product in Japan for life-threatening infectious diseases, as well as chronic granulomatous disease (CGD) and severe, malignant osteopetrosis, two indications for which ACTIMMUNE(R) is already approved in the United States.

"The initiation of clinical programs for ACTIMMUNE(R) in Japan is an important addition to InterMune`s growing global presence," said Dr. Harkonen. "In Japan, the incidence of tuberculosis is four times that of the United States, resulting in 43,000 new cases of tuberculosis each year and 2,000 cases of multidrug-resistant tuberculosis each year. This has led the Japanese Ministry of Health to declare tuberculosis a national emergency." InterMune is currently conducting a U.S. Phase III clinical trial with ACTIMMUNE(R) for the treatment of multidrug-resistant tuberculosis (MDR TB).

InterMune also announced that it plans to develop ACTIMMUNE(R) for the treatment of liver fibrosis (cirrhosis) associated with hepatitis C infection. There are approximately four million people in the United States with hepatitis C, and standard therapy is frequently ineffective. In a clinical study comparing the therapeutic efficacy of interferon gamma and interferon alpha in patients with hepatitis C, the results showed a strong trend towards decreased fibrosis in the patients receiving interferon gamma, compared to no change in patients receiving interferon alpha. In addition, several pre-clinical studies have demonstrated that ACTIMMUNE(R) may prevent and even reverse the fibrosis that forms in the liver as a result of infections or liver toxins. The Company plans to initiate a Phase II clinical trial in the fourth quarter of 2001.

"This is a novel approach to the treatment of liver fibrosis in patients with hepatitis C," said James Pennington, M.D., Executive Vice President of Medical and Scientific Affairs for InterMune. "Standard treatments for hepatitis C address only the virus and not the fibrosis. We believe that ACTIMMUNE(R)`s demonstrated anti-fibrotic activity may reduce the amount of fibrosis in the liver and could work synergistically with standard treatments that address only the viral infection."

InterMune is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis and is in Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and multidrug-resistant tuberculosis (MDR TB). The Company also markets Amphotec(R), an FDA-approved lipid-complexed form of amphotericin B for the treatment of invasive aspergillosis, a life-threatening fungal infection. For more information about InterMune and ACTIMMUNE(R), please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

Except for the historical information contained herein, this press release contains certain forward-looking statements concerning certain of InterMune`s clinical development goals, that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune`s actual results could differ materially from those described in InterMune`s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed under the heading "Risk Factors" and the risks and factors discussed in InterMune`s most recent periodic reports (i.e., 10-K, 10-Q and 8-K) filed with the SEC. In sum, these significant risks include, but are not limited to: the uncertainty of success of InterMune`s efforts in research, development, commercialization, product acceptance, third-party manufacturing and capital raising; the uncertain, lengthy and expensive regulatory process; uncertainties associated with: obtaining and enforcing patents important to its business, being an early-stage company and relying on third-party payors` reimbursement policies; competition from other products; and product liability lawsuits. SOURCE InterMune Pharmaceuticals, Inc.

-0- 04/05/2001

Ciao mastermh

PS: Hat noch jmd interesse an ITMN? (ausser Piddy)

[ZittrigeHand]

hallo@
ITMN...mit einer der unbekannten guten stocks.hier,in germany,unentdeckt.gut zurückgekommen aber auch wieder gut gefangen.ich denke wir werden noch einiges von ITMN hören.
bye all

[ZittrigeHand]

hallo@
ITMN...die letzten tage ausgebrochen....gut so.
mfg,ZH

[mastermh]

InterMune and MoliChem Enter Into Pulmonary Drug Development Collaboration

BURLINGAME, Calif. and CHAPEL HILL, N.C., May 11 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) and MoliChem Medicines, Inc. (OTC: MLCM) announced today the initiation of a collaboration to jointly develop and commercialize MoliChem`s pulmonary molecule Moli1901 (duramycin) for the treatment of a range of pulmonary indications, including cystic fibrosis.

Moli1901 is a mucoactive drug that the companies believe possesses the capability of modifying mucus composition in the airways. Patients with cystic fibrosis have a deficiency of chloride and water in their airways, which prevents proper removal of mucus. This leads to infections, inflammation, tissue damage, and death. Moli1901 induces the transport of chloride and water in the lungs, which facilitates the removal of mucus from the lungs. Treatment with Moli1901 could reduce recurrent infections, inflammation and tissue damage in patients with cystic fibrosis. Moli1901 is currently in a Phase I clinical trial for the treatment of cystic fibrosis.

Cystic fibrosis is the most common inherited fatal disease among Caucasians in the United States. The average life expectancy of a patient with cystic fibrosis is 32 years. There is no cure for cystic fibrosis, and the standard treatments, including antibiotics and mucus thinning therapies, are sub-optimal.

"We are pleased to add such a promising new drug to our pipeline," said W. Scott Harkonen, M.D., President and CEO of InterMune. "This transaction broadens InterMune`s product pipeline and maintains our focus on life-threatening pulmonary and infectious diseases. We plan to continue the expansion of our product portfolio through the strategic in-licensing of development-stage and marketed products."

"This joint development and commercialization structure offers both companies great opportunity for expansion and advancement of our respective goals," said Luis Molina, Ph.D., MoliChem Founder and President. "It capitalizes on InterMune`s resources and experience in pulmonary disease and provides a shared strategic approach to developing and marketing Moli1901."

The terms of the collaboration include an upfront payment of $1.5 million to MoliChem as well as the payment of development milestones to MoliChem for each indication of use. The parties will jointly develop and commercialize Moli1901 for all indications worldwide, sharing all expenses and profits equally. InterMune will lead the commercialization efforts for Moli1901.

Moli1901 is currently in a Phase I safety and pharmacokinetic study in cystic fibrosis patients by aerosol administration, which will soon be completed. The companies expect to begin a Phase II clinical trial for the treatment of cystic fibrosis in the second half of 2001. Cystic fibrosis affects approximately 30,000 individuals in the United States, which represents an annual market opportunity of up to approximately $500 million.

InterMune is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets Actimmune(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis and is in Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and multidrug-resistant tuberculosis (MDR TB). The Company also markets Amphotec(R), an FDA-approved lipid-complexed form of amphotericin B for the treatment of invasive aspergillosis, a life-threatening fungal infection. For more information about InterMune and Actimmune(R), please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

MoliChem Medicines, Inc. is an emerging biotechnology company with a portfolio of potential products for the acute and chronic treatment of serious lung diseases. The company has a broad capability in lung biology with a platform of stable polypeptides, including Moli1901 and two free-radical scavengers in development at the preclinical level, all of which may offer great potential for better lung health.

Except for the historical information contained herein, this press release contains certain forward-looking statements, concerning the possible clinical and financial benefits to InterMune and MoliChem in connection with their joint development and commercialization of Moli1901, that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available as of the date hereof, and InterMune and MoliChem assume no obligation to update any such forward-looking statements or information. InterMune`s and MoliChem`s actual results could differ materially from those described in any of these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: the possibility that the prospective products are not safe or effective, will be uneconomical to manufacture or market, may be precluded from commercialization by the proprietary rights of third parties, or may fail to be as commercially acceptable as and/or cost more than competitors` products. Other factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" and the risks and factors discussed in MoliChem`s most recent Form 10-K filed with the Securities and Exchange Commission ("SEC"); and InterMune`s most recent periodic reports (i.e., 10-K, 10-Q, and 8-K) filed with the SEC, all of which are available to the public. In sum, these significant risks include but are not limited to the present the uncertainty of success of InterMune`s and MoliChem`s efforts to achieve product acceptance, obtain adequate third-party manufacturing and capital-raising; product liability lawsuits; uncertainties associated with obtaining and enforcing patents important to its business; being early-stage companies relying on third-party payors` reimbursement policies; and the uncertain, lengthy, and expensive regulatory processes in the United States and other countries.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X57384453


SOURCE InterMune, Inc.

[mastermh]

Intermune to Present at UBS Warburg Global Specialty Pharmaceutical Conference

BURLINGAME, Calif., May 18 /PRNewswire/ -- InterMune (Nasdaq: ITMN) announced that its presentation to the UBS Warburg Global Specialty Pharmaceutical Conference can be heard live through a listen-only telephone conference line by calling 888-515-2781 or 719-457-2605. The presentation will also be available as a telephone recording following the conference by calling 800-759-8603 or 402-220-8537.

W. Scott Harkonen, M.D., President and CEO of InterMune, will be speaking at The Pierre Hotel in New York, New York on Tuesday, May 22, 2001 at 10:00 a.m. (Eastern).

InterMune is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets Actimmune(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis and is in Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and multidrug-resistant tuberculosis (MDR TB). The company also markets Amphotec(R), an FDA-approved lipid-complexed form of amphotericin B for the treatment of invasive aspergillosis, a life-threatening fungal infection. For more information about InterMune and Actimmune(R), please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X62442924


SOURCE InterMune

[mastermh]

InterMune Honored by National Organization for Rare Disorders (NORD

BURLINGAME, Calif., May 18 /PRNewswire/ -- InterMune (Nasdaq: ITMN) announced today that the company has been honored by the National Organization for Rare Disorders (NORD) for its development of Actimmune(R) (Interferon gamma-1b) for treatment of osteopetrosis. In February 2000, Actimmune(R) became the only FDA-approved treatment for severe, malignant osteopetrosis. InterMune president and chief executive officer W. Scott Harkonen, MD will accept the award at the NORD Annual Tribute Banquet in Washington, D.C. on May 21.

Each year, NORD recognizes outstanding individuals and corporations that have enhanced the lives of people with rare diseases. Senator Orrin Hatch (R-Utah), retired Senators Nancy Kassebaum Baker (R-Kan.) and Mark Hatfield (R-Ore.), and Congressman Henry Waxman (D-Calif.) will serve as Honorary Co-chairs for this celebration. Past award recipients have included Larry King, Senator Diane Feinstein (D-Calif.), and Glaxo Wellcome, Inc.

"We are extremely honored to receive this award from NORD," said Dr. Harkonen. "NORD has recognized our continued cooperation with scientific and patient communities and the federal government, to advance new treatments for life-threatening diseases. In addition to osteopetrosis, InterMune is developing treatments for a number of pulmonary and infectious diseases. Most notably, we are developing Actimmune(R) for treatment of idiopathic pulmonary fibrosis. Actimmune(R) is the first real hope for patients diagnosed with this fatal lung disease."

About InterMune

InterMune is a biotechnology company dedicated to the development and commercialization of innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune currently markets Actimmune(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis and is in Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and multidrug-resistant tuberculosis (MDR TB). The Company also markets Amphotec(R), an FDA-approved colloidal dispersion form of amphotericin B for the treatment of invasive aspergillosis, a life-threatening fungal infection. For more information about InterMune and Actimmune(R), please visit InterMune`s web sites at www.intermune.com and www.actimmune.com, or send e-mail to [e-mail].

About NORD

NORD is a federation of approximately 140 voluntary health organizations and over 70,000 individual patients, healthcare providers and clinical researchers dedicated to helping people with rare "orphan" diseases. There are 25 million Americans suffering with the known 6,000 rare "orphan" diseases in the United States. An orphan disease is defined by the Orphan Drug Act of 1983 as any disease or condition impacting fewer than 200,000 Americans. NORD is committed to the identification, treatment and cure of rare disorders through programs of education, advocacy, research and service.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X14771967


SOURCE InterMune

[mastermh]

Hoffentlich drück dieses nicht zu stark auf den Kurs!

InterMune Announces Filing of Registration Statement For Public Offering of Common Stock

BURLINGAME, Calif., June 4 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed public offering of 3,000,000 shares of its common stock.

Lehman Brothers Inc. will act as sole lead managing underwriter for the offering, and Banc of America Securities LLC, Robertson Stephens, Inc. and UBS Warburg LLC will act as co-managing underwriters. The underwriters have the option to purchase up to an additional 450,000 shares to cover over-allotments, if any.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus relating to the offering may be obtained by contacting Lehman Brothers, 3 World Financial Center, New York, NY 10285, 212-526-7000, or by contacting any of the other underwriters.

InterMune is developing and commercializing innovative products for the treatment of serious pulmonary and infectious diseases and cancer. We market our lead product, Actimmune(R), for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. We are currently conducting a Phase III clinical trial with Actimmune(R) for the treatment of idiopathic pulmonary fibrosis (IPF). We are also conducting or planning clinical trials of Actimmune(R) for the treatment of multidrug-resistant tuberculosis (MDR TB), atypical mycobacterial infections, ovarian cancer, cryptococcal meningitis, cystic fibrosis, and liver fibrosis. We market our second product, Amphotec(R), worldwide for the treatment of invasive aspergillosis.

ciao mastermh

[mastermh]

Hi!

Leider sind ja nicht viele von euch in ITMN investiert! Der Kurs hat sich doch echt gut erholt und strebt an alte Höchststände mit doch rel. guten Umsätzen! Leider habe ich nicht mehr die Zeit hier alle News zu posten und so schreiben ich hier noch mal kurz ein Posting zur "Erinnerung"! Hier ist ein echt guter Player am Start, der leider in D kaum Umsätze aufweist! Vielleicht muss man euch mit der Nase draufstoßen, aber vielleicht reicht auch das posting!

ciao mastermh

PS: wenn ihr ordert, dann nur in USA, da hier eure Order stark verfälscht ausgeführt werden kann! WICHTIG LIMIT!

[Predo]

@ mastermh

Ich bin auch in Intermune investiert, leider bin ich bei über 50$ eingestiegen. Aber der Kurs hat sich super erholt und behauptet sich auch bei der derzeitigen Schwäche im Biotechindex.

Die Frage ist doch warum ist Intermune so stark, was steckt dahinter?

Predo

[mastermh]

Hi!

Ich stell mal nicht mehr alles rein, aber ihr scheint hier nicht zu sehen was mit itmn los ist! die Hürde von $45/46 sollte nun doch genommen werden! Die Umsätze sind stark gestiegen und die Nachrichtenlage ist super! Sind in D keine ITMN-Aktionäre? Ich erinner nur noch mal an dieser Stelle! Take A Look!

ciao mastermh

[mastermh]

KLINGT DOCH ECHT GROßARTIG!!!!


Intermune Announces Positive Clinical Data Using Infergen(R) For the Treatment of Hepatitis C

BRISBANE, Calif., Nov. 12 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced positive interim results from a Phase IV clinical trial comparing the use of Infergen(R) (interferon alfacon-1) plus ribavirin to the use of interferon alfa-2b plus ribavirin (Rebetron(TM)) for the treatment of chronic hepatitis C infections. Patients treated with Infergen(R) in combination with ribavirin achieved a sustained virologic response (SVR) of 56% compared with an SVR of 31% in patients treated with Rebetron(TM). Results were presented at the 52nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Dallas.

"These data suggest that the combination of consensus interferon plus ribavirin is safe and well tolerated and may be more efficacious than Rebetron(TM) therapy," said Col. Maria H. Sjogren, M.D., M.P.H., Chief, Department of Clinical Investigation, Walter Reed Army Medical Center in Washington, D.C. and lead investigator of the Phase IV trial. "We look forward to completion of the study at the end of next year to confirm the potential benefits of this treatment regimen for patients with hepatitis C."

In the study, 127 patients with the hepatitis C virus (HCV) were randomized to receive Infergen(R) plus ribavirin (n=63) or interferon alfa-2b plus ribavirin (n=64) for up to 72 weeks. In an intent-to-treat interim analysis of 70 patients who reached week 72 or discontinued early, researchers observed an SVR rate of 56% in the Infergen(R) plus ribavirin-treated group (19 of 34) compared with 31% in the interferon alfa-2b plus ribavirin group (11 of 35; p=0.032). The rates of discontinuation were similar in both groups. The side effects associated with Infergen(R) are similar to those seen with interferon alfa-2b.

In addition, among gentotype-1 infected patients (n=50), researchers found a 41% SVR rate in the Infergen(R) plus ribavirin-treated group (9 of 22) versus an 18% SVR rate in the interferon alfa-2b plus ribavirin group (5 of 28; p=0.07). Genotype-1-infected patients account for over 60% of the HCV patient population.

"There is a great medical need for alternative therapy for the treatment of hepatitis C because approximately 50% of patients currently fail best available therapy," said W. Scott Harkonen, M.D., President and CEO of InterMune. "This study confirms that Infergen(R) plus ribavirin makes a compelling treatment option for patients, especially those who have failed previous therapies."

About Infergen(R) for Hepatitis C

Infergen(R), also known as consensus interferon (CIFN), is a bioengineered type I interferon alfa indicated for the treatment of patients with chronic hepatitis C infections. Additional clinical trials are ongoing to evaluate varied dosing regimens and duration of therapy to optimize sustained antiviral response. Physicians and patients can obtain additional information about Infergen by visiting http://www.infergen.com .

Hepatitis C is a progressive blood-borne virus that is a primary cause of acute and chronic liver disease in the United States, according to the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK). It accounts for about 20 percent of acute viral hepatitis and 60 to 70 percent of chronic hepatitis. Almost four million Americans have the antibody to HCV (anti-HCV), indicating ongoing or previous infection with the virus. Hepatitis C causes an estimated 8,000 to 10,000 deaths annually in the United States.

InterMune is a commercial-stage biotechnology company dedicated to developing innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune has three marketed products, growing product revenues and advanced-stage clinical programs addressing a range of diseases with attractive commercial markets. For additional information about InterMune, please visit www.intermune.com .

Except for the historical information contained herein, this press release contains certain forward-looking statements concerning certain of InterMune`s financial, business, and clinical development activities and goals that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune`s actual results could differ materially from those described in InterMune`s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed under the heading "Risk Factors" and the risks and factors discussed in InterMune`s most recent periodic reports (i.e., 10-K, 10-Q and 8-K) filed with the SEC. In sum, these significant risks include, but are not limited to: the uncertainty of obtaining and enforcing patents important to InterMune`s business; the uncertainty of success of InterMune`s efforts in research, development, commercialization, product acceptance, third-party manufacturing and capital raising; the uncertain, lengthy and expensive regulatory process; uncertainties associated with: being an early stage company and relying on third-party payors` reimbursement policies; competition from other products; and product liability lawsuits.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X83286640


SOURCE InterMune, Inc.

ciao mastermh

[ZittrigeHand]

jeppa :-))))

[ZittrigeHand]

läuft....läuft....läuft ;-)

[ZittrigeHand]

+ 3,67 %.....hahahaha....

[mastermh]

Hi @ all ITMN Shareholder!!!

Also niemand kann sich jetzt noch beschweren! nur noch 5-8% unter ATH! Also wenn das geknackt wird,...! Ich denke mal dann sollte es richtig losgehen! ITMN macht mir jeden Tag mehr Spass!!

Mir wär mal lieb, wenn alle die ITMN haben hier mal posten, damit wir uns mal alle kennenlernen! Auf zur ITMN Family!!

ciao mastermh

[mastermh]

Also langsam wird unheimlich!!! )

ATH schon heute! Die kaufen ja wie die Wilden! mir solls rechtsein! Aber in D siehts wieder nur mau aus! Also wenn Orders, dann in USA!!!!

ciao mastermh

[ZittrigeHand]

jipppie :-)))

[mastermh]

InterMune Announces Five Abstracts to Be Presented at ICAAC Annual Meeting Highlighting Infectious Disease Pipeline

BRISBANE, Calif., Dec 13, 2001 /PRNewswire via COMTEX/ --
Phase III Oritavancin Results in CSSI and Phase II Actimmune Results in Fungal Infections to Be Presented as Late-Breakers

InterMune, Inc. (Nasdaq: ITMN) today announced that five abstracts related to the Company`s infectious disease development pipeline and research programs will be presented at the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago next week.
Data will be presented from the Company`s first Phase III clinical study with oritavancin for the treatment of complicated skin and skin structure infections. Oritavancin is the Company`s novel glycopeptide antibiotic in development for the treatment of a broad range of Gram-positive bacterial infections. This Phase III study demonstrates oritavancin`s effectiveness against many serious Gram-positive bacteria, including those resistant to conventional antibiotics. Preclinical data on this product`s potential to treat anthrax infections also will be presented.

"The Phase III data being presented at ICAAC demonstrate how oritavancin`s unique benefits, including shorter dosing schedule and favorable resistance profile give it the potential to become a new standard of care for serious Gram-positive bacterial infections," said James Pennington, M.D., InterMune`s Executive Vice President of Medical and Scientific Affairs. "Additional presentations will highlight InterMune`s expanding pipeline of infectious disease programs."

Researchers also will present positive Phase II data for the use of Actimmune(R) (Interferon gamma-1b) as an adjunct to conventional therapy for the treatment of cryptococcal meningitis, a potentially fatal fungal infection of the brain.

In addition, preclinical data regarding the Company`s monoclonal antibody targeted against the PcrV protein of the bacterium Pseudomonas Aeruginosa will be presented.

The Company will host a conference call to discuss the oritavancin and Actimmune results on Tuesday, December 18, at 8:30 a.m. EST. Those interested can call 800-894-4892 (domestic) or 212-748-2746 (international) and reference call number 20083858. The call may also be accessed via webcast through InterMune`s Web Site at www.intermune.com. Please log on 10 minutes prior to the start of the call. A replay will be available by dialing 800-633-8284 (domestic) or 858-812-6440 (international) and referencing call number 20083858.

The five abstracts, which are available upon request or can be downloaded at www.icaac.org, are:



1. Equivalence of Shorter Course Therapy with Oritavancin vs
Vancomycin/Cephalexin in Complicated Skin/Skin Structure Infections (CSSI)
(Late Breaker Poster Session by Dr. Margaret Wasilewski, Eli Lilly and
Company, Indianapolis, IN, on Tue., Dec. 18, 10:30 a.m. CST, Exhibit
Hall);

2. Abstract #LB-10: Adjunctive Interferon Gamma (IFNg) for Treatment of
Cryptococcal Meningitis (Crypto): A Randomized, Double-Blind Pilot Trial
(Late-Breaker Slide Session by Dr. P.G. Pappas, University of Alabama,
Birmingham, AL, on Tue., Dec. 18, 12:00 p.m. CST, Arie Crown Theatre);

3. Abstract #524: In Vitro Activity of Oritavancin (LY333328),
Levofloxacin, Meropenem, GAR936 and Linezolid against strains of Bacillus
Anthracis (Poster Presentation by Dr. Henry S. Heine, Bacteriology
Division, U.S. Army Medical Research Institute of Infectious Diseases, Ft.
Detrick, MD, on Sun., Dec. 16, 3:00 p.m. CST, Exhibit Hall);

4. Abstract #2193: Protein Binding of 14C-Oritavancin (Poster
Presentation by Dr. T. J. Brown, Lilly Research Lab, Indianapolis, IN, on
Wed., Dec. 19, 10:00 a.m. CST, Room E354A);

5. Abstract #997: Development and Characterization of Monoclonal
Antibody to Pseudomonas Aeruginosa Type III Secreted Protein PcrV (Poster
Presentation by Dr. Teiji Sawa, University of California, San Francisco,
San Francisco, CA, on Mon., Dec. 17, 1:30 p.m. CST, Exhibit Hall).

About InterMune
InterMune is a commercial-stage biotechnology company dedicated to developing innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune has three marketed products, growing product revenues and advanced-stage clinical programs addressing a range of diseases with attractive commercial markets. For additional information about InterMune, please visit www.intermune.com.

Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties concerning certain of InterMune`s clinical development activities and goals, including without limitation statements concerning: oritavancin`s efficacy against serious Gram-positive infections, shorter dosing schedule and favorable resistance profile; and positive Phase II clinical data for the use of Actimmune as adjunctive therapy to treat cryptococcal meningitis. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune`s actual results could differ materially from those described in InterMune`s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed in detail under the heading "Risk Factors" and the other risks and factors discussed in InterMune`s 8-K reports filed with the SEC on June 29, 2001 and September 19, 2001, and other periodic reports (i.e., 10-K, 10-KA, 10-Q and 8-K) filed with the SEC, which are incorporated herein by reference. The risks and other factors that follow, concerning the forward-looking statements in this press release, should be considered only in connection with the fully discussed risks and other factors discussed in detail in the two 8-K reports and InterMune`s other periodic reports filed with the SEC. InterMune`s forward-looking statements concerning oritavancin`s efficacy against Gram-positive infections, shorter dosing schedule and favorable resistance profile; and Actimmune`s efficacy against cryptococcal meningitis are subject to the uncertainties and risks associated with the uncertain, lengthy and expensive drug research and development and regulatory process; budget constraints; third-party manufacturers; competition; and InterMune`s ability to obtain, maintain and enforce patents and other intellectual property.



MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X57982466

SOURCE InterMune, Inc.

DER KURSANSTIEG SCHEINT DOCH BERECHTIGT!!!
UND DER KURZE RÜCKSETZER IST DOCH AUCH POSITIV UND GESUND ZU SEHEN!!

ciao mastermh

[Predo]

@ mastermh

Was ist los bei Intermune? Finde keine News die den Kurs so unter Druck bringen könnten.

Predo

[ZittrigeHand]

tja,sie fallen wie all die andren...FDA effekt ;-)
hab sie,gott sei dank, vor x-mas rausgehauen.......
werde die 40.ger zone beobachten...und ggf.neu einsteigen..
die anleger waren in den letzten tagen halt auf soxx`s
fixiert...aber,kein grund in panik zu verfallen ;-)
*zitter*

[Predo]

Monday January 7, 6:01 am Eastern Time

Press Release
SOURCE: InterMune, Inc.

InterMune Receives Fast Track Designation From FDA for Actimmune In the Treatment of Idiopathic Pulmonary Fibrosis
- Phase III IPF Study Maintains Strong Patient Retention -

BRISBANE, Calif., Jan. 7 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN - news) announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for Actimmune® (Interferon gamma-1b) injection for the treatment of idiopathic pulmonary fibrosis (IPF), a debilitating and usually fatal disease for which there is no effective therapy.

Fast Track programs are designed to facilitate the development and review of new drugs that are intended to treat life-threatening conditions and reflect the potential to address significant unmet medical needs. The FDA stated, in part, in its letter to InterMune, that `` ... we are designating as a Fast Track development program the investigation of Interferon gamma-1b for its effects on progression free survival in patients with idiopathic pulmonary fibrosis who are unresponsive to steroids.``

``Actimmune is the first and only drug to receive Fast Track designation for IPF,`` said W. Scott Harkonen, MD, President and Chief Executive Officer of InterMune. ``Official Fast Track status for this indication will help accelerate review and approval of this potentially important treatment for patients suffering from this life-threatening condition.

``We look forward to announcing the results of the Phase III trial for IPF by November 2002 and plan to work closely with the agency as we submit our marketing application at the end of the year,`` added Dr. Harkonen.

In addition, the Company reported that in its ongoing Phase III trial for IPF, approximately 60% of the trial is complete in terms of patient treatment days. Furthermore, less than 5% of patients have withdrawn from the study prior to meeting the primary endpoint. This retention rate is well within the assumptions underlying the statistical power and sample size of the 330-patient trial.

Dr. Harkonen also stated, ``We are very pleased with this high level of patient retention as of January and expect that patient retention going forward will continue to be strong. We would like to thank all participating investigators, coordinators and patients for their tremendous commitment and dedication to this trial.``

IPF is characterized by progressive scarring, or fibrosis of the lungs, which ultimately leads to respiratory failure. The prognosis is poor for patients with IPF and the median life span is three to five years from the time of diagnosis. There are approximately 50,000 patients in the United States suffering from IPF, which occurs primarily in persons 40 to 70 years old. Actimmune is the first and only drug to have shown promise as a treatment for IPF in a Phase II clinical trial.

About Actimmune

Actimmune is an approved product on the market for the treatment of two rare congenital diseases, chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. InterMune is conducting or planning to conduct multiple Phase II and three Phase III clinical studies with Actimmune, including the Phase III clinical trial for the treatment of IPF.

InterMune recently reported positive results from a Phase II clinical trial examining the use of Actimmune in combination with amphotericin B for the treatment of cryptococcal meningitis, a difficult-to-treat and life-threatening fungal infection. The Company plans to initiate a Phase III trial of Actimmune for the treatment of ovarian cancer. Studies are also ongoing with Actimmune for the treatment of cystic fibrosis and atypical mycobacterial infections.

About InterMune

InterMune is a commercial-stage biotechnology company dedicated to developing innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune has three marketed products, growing product revenues and advanced-stage clinical programs addressing a range of diseases with attractive commercial markets. For additional information about InterMune, please visit www.intermune.com.

Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation statements indicating that InterMune: looks forward to announcing results of the IPF Phase III clinical trial in November 2002; is planning to conduct multiple Phase II and Phase III clinical studies with Actimmune; plans to submit a marketing application with the FDA for IPF; expects patient retention to be strong through the completion of the IPF trial; and plans to initiate a Phase III trial of Actimmune for the treatment of ovarian cancer. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune`s actual results could differ materially from those described in InterMune`s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed in detail under the heading ``Risk Factors`` and the other risks and factors discussed in InterMune`s 8-K report filed with the SEC on December 21, 2001, and other periodic reports (i.e., 10-K, 10-KA, 10-Q and 8-K) filed with the SEC, which are incorporated herein by reference. The risks and other factors that follow, concerning the forward-looking statements in this press release, should be considered only in connection with the fully discussed risks and other factors discussed in detail in the 8-K report and InterMune`s other periodic reports filed with the SEC. InterMune`s forward-looking statements in this press release concerning Actimmune or Actimmune timelines are subject to the uncertainties and risks associated with the uncertain, lengthy and expensive drug research and development and regulatory process; budget constraints; third-party manufacturers; significant competition; and InterMune`s ability to obtain, maintain and enforce patents and other intellectual property. InterMune`s forward-looking statement in this press release concerning patient retention continuing to be strong in connection with the Phase III clinical trial for IPF are subject to the risks and uncertainties that trial subjects may become impatient with the progression of their illness and withdraw from the trial.

SOURCE: InterMune, Inc.

[mastermh]

hallo @ all!

also da der gewinn oder verlust höher war als erwartet sollte niemanden abschrecken! nur ärgert mich wirklich das interesse an deutschen aktionären bei itmn! die news sind fast ausschließlich positiv und bei den threads findet sich niemand der beiträge posted und so weiter! warum findet sich hier nicht eine kleine gemeinschaft? und da ich zZ wirklich kaum zeit habe würde ich mich freuen wenn andere die news posten und meinungen schreiben! naja jedenfalls hält sich itmn super und der rückgang ist doch positiv als gute und gesunde bewegung zu sehen! nur spielt der markt nicht ganz so mit!

stay happy

ciao mastermh